Eli Lilly and Company (NYSE:LLY) Shares Sold by Northcape Wealth Management LLC

Northcape Wealth Management LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,287 shares of the company’s stock after selling 619 shares during the quarter. Eli Lilly and Company comprises 1.5% of Northcape Wealth Management LLC’s portfolio, making the stock its 15th largest position. Northcape Wealth Management LLC’s holdings in Eli Lilly and Company were worth $4,248,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 6.3% in the 4th quarter. Brighton Jones LLC now owns 9,674 shares of the company’s stock worth $5,639,000 after buying an additional 577 shares in the last quarter. Vanguard Capital Wealth Advisors boosted its stake in Eli Lilly and Company by 10.1% during the 4th quarter. Vanguard Capital Wealth Advisors now owns 545 shares of the company’s stock valued at $318,000 after purchasing an additional 50 shares in the last quarter. Mission Wealth Management LP boosted its stake in Eli Lilly and Company by 0.4% during the 4th quarter. Mission Wealth Management LP now owns 7,213 shares of the company’s stock valued at $4,204,000 after purchasing an additional 26 shares in the last quarter. Stonebridge Financial Planning Group LLC boosted its stake in Eli Lilly and Company by 135.0% during the 4th quarter. Stonebridge Financial Planning Group LLC now owns 1,034 shares of the company’s stock valued at $603,000 after purchasing an additional 594 shares in the last quarter. Finally, Certuity LLC boosted its stake in Eli Lilly and Company by 319.3% during the 4th quarter. Certuity LLC now owns 9,933 shares of the company’s stock valued at $5,790,000 after purchasing an additional 7,564 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 6.0 %

LLY traded up $44.36 during trading on Tuesday, reaching $781.56. 7,432,651 shares of the stock traded hands, compared to its average volume of 3,071,009. The stock has a market cap of $742.61 billion, a price-to-earnings ratio of 134.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $392.26 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock’s 50-day simple moving average is $760.89 and its two-hundred day simple moving average is $668.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.09 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wells Fargo & Company increased their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Finally, BMO Capital Markets raised their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $731.55.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.